TY - JOUR
T1 - Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines
AU - On behalf of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)
AU - Bowen, Joanne M.
AU - Gibson, Rachel J.
AU - Coller, Janet K.
AU - Blijlevens, Nicole
AU - Bossi, Paolo
AU - Al-Dasooqi, Noor
AU - Bateman, Emma H.
AU - Chiang, Karen
AU - de Mooij, Charlotte
AU - Mayo, Bronwen
AU - Stringer, Andrea M.
AU - Tissing, Wim
AU - Wardill, Hannah R.
AU - van Sebille, Ysabella Z.A.
AU - Ranna, Vinisha
AU - Vaddi, Anusha
AU - Keefe, Dorothy Mk
AU - Lalla, Rajesh V.
AU - Cheng, Karis Kin Fong
AU - Elad, Sharon
N1 - Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Purpose: The aim of this study was to update the clinical practice guidelines for the use of agents for the prevention and/or treatment of gastrointestinal mucositis (GIM). Methods: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: Recommendation, Suggestion, and No Guideline Possible. Results: A total of 78 papers across 13 interventions were examined of which 25 were included in the final review. No new guidelines were possible for any agent due to inadequate and/or conflicting evidence. Existing guidelines for probiotics and hyperbaric oxygen were unchanged. Conclusions: Of the agents studied for the prevention and treatment of GIM, the evidence continues to support use of probiotics containing Lactobacillus spp. for prevention of chemoradiotherapy and radiotherapy-induced diarrhea in patients with pelvic malignancy, and hyperbaric oxygen therapy to treat radiation-induced proctitis. Additional well-designed research is encouraged to enable a decision regarding palifermin, glutamine, sodium butyrate, and dietary interventions, for the prevention or treatment of GIM.
AB - Purpose: The aim of this study was to update the clinical practice guidelines for the use of agents for the prevention and/or treatment of gastrointestinal mucositis (GIM). Methods: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: Recommendation, Suggestion, and No Guideline Possible. Results: A total of 78 papers across 13 interventions were examined of which 25 were included in the final review. No new guidelines were possible for any agent due to inadequate and/or conflicting evidence. Existing guidelines for probiotics and hyperbaric oxygen were unchanged. Conclusions: Of the agents studied for the prevention and treatment of GIM, the evidence continues to support use of probiotics containing Lactobacillus spp. for prevention of chemoradiotherapy and radiotherapy-induced diarrhea in patients with pelvic malignancy, and hyperbaric oxygen therapy to treat radiation-induced proctitis. Additional well-designed research is encouraged to enable a decision regarding palifermin, glutamine, sodium butyrate, and dietary interventions, for the prevention or treatment of GIM.
KW - Clinical management
KW - Gastrointestinal
KW - Guidelines
KW - Mucositis
UR - http://www.scopus.com/inward/record.url?scp=85068881769&partnerID=8YFLogxK
U2 - 10.1007/s00520-019-04892-0
DO - 10.1007/s00520-019-04892-0
M3 - Article
C2 - 31286233
AN - SCOPUS:85068881769
SN - 0941-4355
VL - 27
SP - 4011
EP - 4022
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 10
ER -
